KROS — Keros Therapeutics Share News
0.000.00%
Last trade - 00:00- $223.65m
- -$33.96m
- $244.06m
Keros Therapeutics Inc expected to post a loss of $1.28 a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Cigna, Marriott, Ralph Lauren
Brief: Keros Therapeutics Completes Enrollment Of Tropos Phase 2 Trial
U.S. STOCKS ON THE MOVE-US energy sector, gold miners, AeroVironment
U.S. STOCKS ON THE MOVE-Meta, US energy sector, gold miners
U.S. STOCKS ON THE MOVE-Danimer Scientific, Constellation Energy, Elevai Labs
U.S. STOCKS ON THE MOVE-Constellation Energy, Nuvve Holding, Intel
Guggenheim starts Keros Therapeutics with 'buy' on lung disorder drug potential
Brief: Keros Therapeutics Announces Update On Enrollment In The Phase 2 TROPOS Trial
Keros Therapeutics Inc reports results for the quarter ended in January - Earnings Summary
Brief: Keros Therapeutics Q2 EPS USD -1.25
Keros Therapeutics Inc expected to post a loss of $1.23 a share - Earnings Preview
Brief: Keros Therapeutics Filed Prospectus Supplement To Co's Shelf Registration Statement For Issuance & Sale Of Up To $350 Mln Shares Of Common Stock
Brief: Keros Therapeutics Announces Leadership Updates
Brief: Keros Therapeutics Q1 EPS USD -1.21
Brief: Keros Therapeutics Files For Mixed Shelf Size Not Disclosed - SEC Filing
Keros Therapeutics Inc expected to post a loss of $1.35 a share - Earnings Preview
Keros Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Keros Therapeutics Q4 EPS USD -1.34